Denali Therapeutics (NASDAQ:DNLI) Insider Sells $11,799.84 in Stock

Key Points

• Carole Ho, an insider at Denali Therapeutics, sold 806 shares for a total of $11,799.84 on August 13, reducing her position by 0.37% and retaining 216,585 shares valued at approximately $3.17 million.
• Denali Therapeutics reported a loss of $0.72 earnings per share in its latest quarterly results, slightly better than the consensus estimate of a loss of $0.74.
• Despite recent insider selling, Denali Therapeutics has seen positive ratings from analysts, with an average price target of $33.85 and a prevailing rating of "Buy."

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Carole Ho sold 806 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $14.64, for a total transaction of $11,799.84. Following the sale, the insider directly owned 216,585 shares in the company, valued at approximately $3,170,804.40. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Carole Ho also recently made the following trade(s):

• On Tuesday, August 12th, Carole Ho sold 2,937 shares of Denali Therapeutics stock. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46.

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $0.1350 during mid-day trading on Tuesday, hitting $14.6850. 191,318 shares of the stock were exchanged, compared to its average volume of 1,404,887. The firm has a fifty day moving average of $14.30 and a 200 day moving average of $15.19. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The company has a market cap of $2.15 billion, a PE ratio of -5.24 and a beta of 1.36.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the previous year, the business earned ($0.59) earnings per share. Research analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. Envestnet Asset Management Inc. increased its holdings in shares of Denali Therapeutics by 34.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 37,622 shares of the company's stock worth $767,000 after buying an additional 9,643 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $533,000. Sterling Capital Management LLC increased its holdings in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. Barclays PLC increased its holdings in Denali Therapeutics by 8.7% in the 4th quarter. Barclays PLC now owns 278,067 shares of the company's stock valued at $5,666,000 after purchasing an additional 22,184 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Denali Therapeutics in the 4th quarter valued at approximately $328,000. Institutional investors and hedge funds own 92.92% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DNLI. Robert W. Baird decreased their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. William Blair raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. HC Wainwright cut their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Bank of America cut their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Buy" and a consensus price target of $33.62.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.